
Janssen has entered a clinical trial collaboration and supply agreement with Onyx to evaluate the efficacy and safety of Darzalex, the first-in-class CD38-directed immunotherapy daratumumab, in combination with a proteasome inhibitor carfilzomib and dexamethasone.















